electroCore, Inc.

electroCore is a bioelectronic technology company focused on non-invasive bioelectronic technologies. The company's two main commercial products are gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell Fibromyalgia (Quell). Additionally, electroCore sells Truvaga and TAC-STIM, which are handheld, personal-use consumer products for general wellness and human performance. The company's proprietary nVNS technology and Quell for chronic pain are designed to address limitations of traditional non-invasive approaches. electroCore generates revenue from selling prescription medical devices and non-prescription wellness products in the United States and select overseas markets. The company has two primary product categories: personal use prescription medical devices for managing and treating conditions like primary headache and fibromyalgia, and personal use consumer products for general wellness and human performance. The company's capabilities include product development, regulatory affairs and compliance, sales and marketing, product testing, electromechanical assembly, fulfillment, intellectual property, and customer support. gammaCore is a prescription, handheld medical device that is FDA cleared for various primary headache conditions. gammaCore products are available by prescription only, are portable, reusable, rechargeable, and offer reloadable personal use options. Prescriptions are written by a healthcare provider and dispensed from a specialty pharmacy, through the patient's healthcare system, or directly from electroCore's facility in Rockaway, New Jersey. Additional therapy for certain gammaCore products can be refilled with a prescription authorization.